Thyroid Cancer Trial Results
- Sorafenib Improves Progression-Free Survival in Some Patients with Metastatic Thyroid Cancer
(Posted: 05/27/2014) - Results from an international phase III trial show that sorafenib (Nexavar®) may benefit patients with locally advanced or metastatic differentiated thyroid cancer that is no longer responding to treatment with radioactive iodine. Patients who were treated with sorafenib lived longer without their cancers getting worse than patients who received a placebo.
- Low-Dose Radioactive Iodine Destroys Thyroid Tissue Left after Surgery
(Posted: 06/07/2012) - A low dose of radioactive iodine given after surgery for thyroid cancer destroyed (ablated) residual thyroid tissue as effectively as a higher dose, with fewer side effects and less exposure to radiation, according to two European randomized controlled trials published May 3, 2012 in the New England Journal of Medicine.
- Targeted Therapy Shows Benefit in Rare Type of Thyroid Cancer
(Posted: 12/02/2011) - Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.